Receive Our Newsletter

Genentech Announces Positive Phase III Results for Emicizumab at ISTH 2017

industry_news_banner

Note: The following is an edited version of a press release from Genentech. Read the press release from Genentech in it’s entirety here.


Genentech, a member of the Roche Group, announced today that data from HAVEN 1, a Phase III study evaluating once-weekly subcutaneous emicizumab prophylaxis (preventative) in adults and adolescents with hemophilia A with inhibitors, were published in The New England Journal of Medicine (NEJM). The primary endpoint showed a clinically meaningful and statistically significant reduction in treated bleeds of 87 percent (risk rate [RR]=0.13, p<0.0001) with emicizumab prophylaxis compared with on-demand (no prophylaxis; episodic use only) bypassing agents (BPAs). Data from HAVEN 1 and the interim analysis of the Phase III HAVEN 2 study of emicizumab in children are being presented at the 26th International Society on Thrombosis and Haemostasis (ISTH) Congress today.

Comments (No comments)

Assisting and Advocating for the Bleeding Disorders Community